Journal Article

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Hansell, David M, Flaherty, Kevin R, Cottin, Vincent, Kolb, Martin, Stowasser, Susanne, Raghu, Ganesh, Noble, Paul W, Inoue, Yoshikazu, Taniguchi, Hiroyuki, Azuma, Arata, Nicholson, Andrew G, du Bois, Roland M, Costabel, Ulrich, Brun, Michèle, Brown, Kevin K, Kim, Dong Soon, Le Maulf, Florence, Collard, Harold R, Girard, Mannaïg, Schlenker-Herceg, Rozsa, Richeldi, Luca, Selman, Moisés, Disse, Bernd

2014

Overview

In this randomized, placebo-controlled trial, treatment with nintedanib, an intracellular inhibitor of multiple tyrosine kinases, led to a reduced rate of loss of forced vital capacity in patients with idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis is a fatal lung disease characterized by worsening dyspnea and progressive loss of lung function. 1 A decline in forced vital capacity (FVC) is consistent with disease progression and is predictive of reduced survival time. 1 – 6 Idiopathic pulmonary fibrosis is believed to arise from an aberrant proliferation of fibrous tissue and tissue remodeling due to the abnormal function and signaling of alveolar epithelial cells and interstitial fibroblasts. 7 The activation of cell-signaling pathways through tyrosine kinases such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) has been implicated in the pathogenesis of . . .

• Publisher: Massachusetts Medical Society
• Subject: Aged / Biological and medical sciences / Biopsy / Clinical trials / Diarrhea / Disease Progression / Double-Blind Method / Drug therapy / Enzyme Inhibitors - administration & dosage / Enzyme Inhibitors - adverse effects / Female / Fibrosis / General aspects / Humans / Idiopathic Pulmonary Fibrosis - drug therapy / Idiopathic Pulmonary Fibrosis - physiopathology / Indoles - administration & dosage / Indoles - adverse effects / Lung diseases / Male / Medical sciences / Middle Aged / Patients / Pneumology / Protein Kinase Inhibitors - administration & dosage / Protein Kinase Inhibitors - adverse effects / Protein-Tyrosine Kinases - antagonists & inhibitors / Pulmonary fibrosis / Quality of Life / Respiratory function / Respiratory system : syndromes and miscellaneous diseases / Treatment Outcome / Tyrosine / Vascular endothelial growth factor / Vital Capacity - drug effects